树突状细胞对多发性骨髓瘤的细胞免疫治疗。

The Korean Journal of Hematology Pub Date : 2012-03-01 Epub Date: 2012-03-28 DOI:10.5045/kjh.2012.47.1.17
Thanh-Nhan Nguyen-Pham, Youn-Kyung Lee, Hyun-Ju Lee, Mi-Hyun Kim, Deok-Hwan Yang, Hyeoung-Joon Kim, Je-Jung Lee
{"title":"树突状细胞对多发性骨髓瘤的细胞免疫治疗。","authors":"Thanh-Nhan Nguyen-Pham,&nbsp;Youn-Kyung Lee,&nbsp;Hyun-Ju Lee,&nbsp;Mi-Hyun Kim,&nbsp;Deok-Hwan Yang,&nbsp;Hyeoung-Joon Kim,&nbsp;Je-Jung Lee","doi":"10.5045/kjh.2012.47.1.17","DOIUrl":null,"url":null,"abstract":"<p><p>Cellular therapy with dendritic cells (DCs) is emerging as a useful immunotherapeutic tool to treat multiple myeloma (MM). DC-based idiotype vaccination was recently suggested to induce idiotype-specific immune responses in MM patients. However, the clinical results so far have been largely disappointing, and the clinical effectiveness of such vaccinations in MM still needs to be demonstrated. DC-based therapies against MM may need to be boosted with other sources of tumor-associated antigens, and potent DCs should be recruited to increase the effectiveness of treatment. DCs with both high migratory capacity and high cytokine production are very important for effective DC-based cancer vaccination in order to induce high numbers of Th1-type CD4(+) T cells and CD8(+) cytotoxic T lymphocytes. The tumor microenvironment is also important in the regulation of tumor cell growth, proliferation, and the development of therapeutic resistance after treatment. In this review, we discuss how the efficacy of DC vaccination in MM can be improved. In addition, novel treatment strategies that target not only myeloma cells but also the tumor microenvironment are urgently needed to improve treatment outcomes.</p>","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 1","pages":"17-27"},"PeriodicalIF":0.0000,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.1.17","citationCount":"11","resultStr":"{\"title\":\"Cellular immunotherapy using dendritic cells against multiple myeloma.\",\"authors\":\"Thanh-Nhan Nguyen-Pham,&nbsp;Youn-Kyung Lee,&nbsp;Hyun-Ju Lee,&nbsp;Mi-Hyun Kim,&nbsp;Deok-Hwan Yang,&nbsp;Hyeoung-Joon Kim,&nbsp;Je-Jung Lee\",\"doi\":\"10.5045/kjh.2012.47.1.17\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cellular therapy with dendritic cells (DCs) is emerging as a useful immunotherapeutic tool to treat multiple myeloma (MM). DC-based idiotype vaccination was recently suggested to induce idiotype-specific immune responses in MM patients. However, the clinical results so far have been largely disappointing, and the clinical effectiveness of such vaccinations in MM still needs to be demonstrated. DC-based therapies against MM may need to be boosted with other sources of tumor-associated antigens, and potent DCs should be recruited to increase the effectiveness of treatment. DCs with both high migratory capacity and high cytokine production are very important for effective DC-based cancer vaccination in order to induce high numbers of Th1-type CD4(+) T cells and CD8(+) cytotoxic T lymphocytes. The tumor microenvironment is also important in the regulation of tumor cell growth, proliferation, and the development of therapeutic resistance after treatment. In this review, we discuss how the efficacy of DC vaccination in MM can be improved. In addition, novel treatment strategies that target not only myeloma cells but also the tumor microenvironment are urgently needed to improve treatment outcomes.</p>\",\"PeriodicalId\":23001,\"journal\":{\"name\":\"The Korean Journal of Hematology\",\"volume\":\"47 1\",\"pages\":\"17-27\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.5045/kjh.2012.47.1.17\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Korean Journal of Hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5045/kjh.2012.47.1.17\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2012/3/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Korean Journal of Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5045/kjh.2012.47.1.17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/3/28 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

摘要

树突状细胞(dc)细胞治疗正在成为治疗多发性骨髓瘤(MM)的有效免疫治疗工具。基于dc的独特型疫苗最近被建议在MM患者中诱导独特型特异性免疫反应。然而,迄今为止的临床结果在很大程度上令人失望,这种疫苗在MM中的临床有效性仍有待证实。针对MM的基于dc的治疗可能需要与其他肿瘤相关抗原来源一起加强,并且应该招募有效的dc来增加治疗的有效性。具有高迁移能力和高细胞因子产生的dc对于有效的dc肿瘤疫苗接种非常重要,以诱导大量th1型CD4(+) T细胞和CD8(+)细胞毒性T淋巴细胞。肿瘤微环境在调节肿瘤细胞生长、增殖和治疗后耐药性的发展中也很重要。在这篇综述中,我们讨论了如何在MM中提高DC疫苗的疗效。此外,迫切需要新的治疗策略,不仅针对骨髓瘤细胞,还针对肿瘤微环境,以改善治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Cellular immunotherapy using dendritic cells against multiple myeloma.

Cellular therapy with dendritic cells (DCs) is emerging as a useful immunotherapeutic tool to treat multiple myeloma (MM). DC-based idiotype vaccination was recently suggested to induce idiotype-specific immune responses in MM patients. However, the clinical results so far have been largely disappointing, and the clinical effectiveness of such vaccinations in MM still needs to be demonstrated. DC-based therapies against MM may need to be boosted with other sources of tumor-associated antigens, and potent DCs should be recruited to increase the effectiveness of treatment. DCs with both high migratory capacity and high cytokine production are very important for effective DC-based cancer vaccination in order to induce high numbers of Th1-type CD4(+) T cells and CD8(+) cytotoxic T lymphocytes. The tumor microenvironment is also important in the regulation of tumor cell growth, proliferation, and the development of therapeutic resistance after treatment. In this review, we discuss how the efficacy of DC vaccination in MM can be improved. In addition, novel treatment strategies that target not only myeloma cells but also the tumor microenvironment are urgently needed to improve treatment outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Long-term survival of a patient with bone marrow gelatinous degeneration of idiopathic origin. Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells. Prognostic significance of gelsolin and MMP12 in Langerhans cell histiocytosis. Central nervous system (CNS) involvement is a critical prognostic factor for hemophagocytic lymphohistiocytosis. Surgery in patients with congenital factor VII deficiency: A single center experience.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1